Effect of Adjunctive Systemic Azithromycin With Periodontal Surgery in the Treatment of Chronic Periodontitis in Smokers: A Pilot Study by Dastoor, Sarosh F. et al.
Effect of Adjunctive Systemic
Azithromycin With Periodontal Surgery
in the Treatment of Chronic Periodontitis
in Smokers: A Pilot Study
Sarosh F. Dastoor,* Suncica Travan,* Rodrigo F. Neiva,* Lindsay A. Rayburn,*
William V. Giannobile,*† and Hom-Lay Wang*
Background: Along with conventional surgical therapy, systemic anti-
biotics may provide more effective treatment in smokers by targeting tis-
sue-invasive bacteria. The aim of this randomized, placebo-controlled,
double-masked clinical trial was to evaluate the adjunctive effects of sys-
temic azithromycin (AZM) in combination with periodontal pocket reduc-
tion surgery in the treatment of chronic periodontitis in smokers.
Methods: Thirty patients with a greater than one pack/day smoking
habit and generalized moderate to severe chronic periodontitis were ran-
domized to the test (surgery plus 3 days of AZM, 500 mg) or control group
(surgery plus 3 days of placebo). Full-mouth probing depth (PD), clinical
attachment level (CAL), bleeding on probing (BOP), gingival index (GI),
plaque index, and wound healing indices (WHI) were assessed at baseline
and at 2 weeks and 1, 3, and 6 months following surgical intervention.
Plaque and gingival crevicular fluid were collected for trypsin-like enzyme
activity (benzoyl-dl-arginine naphthylamine) and bone biomarker (cross-
linked telopeptide of type I collagen [ICTP]) analyses, respectively, at
baseline, 2 weeks, and 1, 3, and 6 months.
Results: Surgical treatment of moderate (PD = 4 to 6 mm) and deep (PD
>6 mm) pockets significantly improved clinical parameters of treated and
untreated teeth (CAL gain, PD reduction, and reduction of BOP). The ad-
ditional use of AZM did not enhance this improvement nor did it promote
reduction of ICTP levels. Compared to the control group, the test group
had significantly better WHI scores at 1 month, significantly less GI at 2
weeks, and sustained reductions of red-complex bacteria with trypsin-
like enzyme activity at 3 months. For non-surgery teeth, only the test
group showed significant gains in overall CAL compared to baseline.
Conclusions: The findings of this pilot study demonstrated that in heavy
smokers, adjunctive systemic AZM in combination with pocket reduction
surgery did not significantly enhance PD reduction or CAL gain. However,
the clinical value of adjunctive AZM may be appreciated by more rapid
wound healing, less short-term gingival inflammation, and sustained re-
ductions of periopathogenic bacteria. More expanded studies are recom-
mended to better determine the clinical effects of adjunctive AZM in
patients who smoke. J Periodontol 2007;78:1887-1896.
KEY WORDS
Antibiotic; azithromycin/therapeutic use; periodontitis/drug therapy;




titis is quite effective,
it has certain limitations.
Complete calculus removal
is not possible for teeth that
have probing depth (PD) ‡3
mm or in posterior teeth with
furcation involvements.1,2
To overcome the limitations
of non-surgical therapy and
facilitate long-term mainte-
nance of shallow PD, sur-
gical treatments, such as
gingivectomy, Widman and
modified Widman flaps, and
apically positioned flaps with
or without osseous surgery,
were developed.3-5 Despite
the valuable benefits of these
therapies, long-term results
have not shown convincing
superiority over non-surgical
treatment modalities in terms
of clinical attachment level
(CAL) gain.6,7 Nonetheless,
advantages of PD reduction
surgery (apically positioned
flap with or without osse-
ous recontouring) might be
appreciated in terms of
sustained long-term PD re-
duction which, in turn, pro-
motes decreased niches for
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pathogenic bacteria that can negatively affect treated
and untreated teeth.8,9 This type of surgery yields the
greatest proportion of shallow PD (1 to 3 mm) and
the least percentage of sites that break down in the
long term.7,10
Smoking is a major risk factor in the initiation and
progression of periodontal disease.11,12 In general,
studies have shown that smoking increases the risk
for developing periodontal disease by twofold to five-
fold, and these effects seem to be dose dependent.
Smoking leads to a greater risk for CAL loss, greater
numbers of deep PD, increased prevalence and sever-
ity of vertical bony defects, and higher counts of some
putative periodontal pathogens. Additionally, smok-
ing alters the host immune response by decreasing
its ability to combat pathogens effectively.12,13 Some
mechanisms include the altered chemotactic and
phagocytic abilities of neutrophils and macrophages
in smokers, decreased sera immunoglobulin G anti-
body titers to periodontal pathogens, and increased
generation of proinflammatory molecules, such as
PGE2, elastase, and matrix metalloproteinase-8. As
a result, smokers exhibit a higher prevalence of
edentulism and a greater incidence of tooth loss.14
As a result, smokers tend to have a less favorable
therapeutic response to non-surgical or surgical ther-
apy.15-17 Generally, smokers demonstrate less PD re-
duction and CAL gain following therapy. This may be
due to the fact that smokers tend to harbor more peri-
odontal pathogens before and even after therapy,
which may contribute to inferior results.18 Addition-
ally, it has been shown consistently that smokers tend
to accumulate more plaque than non-smokers, which
may explain, in part, their inability to sustain PD re-
duction.19
Because smoking impairs the result of most con-
ventional treatments of chronic periodontitis, it is im-
perative to investigate adjuncts to treatment that may
enhance healing. Systemic antibiotics have proven to
be beneficial after non-surgical20 and surgical ther-
apy.21 A recent systematic review found that system-
ically administered antibiotics exhibited statistically
significantly more CAL gain than in control groups with
no antibiotics.22 This review noted that antibiotics
were beneficial when used as adjuncts to scaling and
root planing (SRP) plus periodontal surgery or when
used as a stand-alone therapy, although the investi-
gators noted that this was of borderline significance.
Azithromycin (AZM) is a systemic antibiotic that
has not been evaluated extensively as an adjunct in
the treatment of periodontal disease. AZM belongs
to a class of macrolide antibiotics called azalides. It
has better oral absorption than other antibiotics in
the same class because of higher resistance to gastric
acids. Macrolides work in a bacteriostatic fashion by
interfering with the 50s component of the bacterial ri-
bosome, thus inhibiting translation of mRNA and pre-
venting proper protein synthesis. AZM’s antimicrobial
spectrum is similar to erythromycin; however, it is
more effective against certain Gram-negative bacte-
ria, especially Actinobacillus actinomycetemcomi-
tans.23 This antibiotic is effective against systemic,
intraoral, and facial infections.24,25
Unlike other antibiotics, AZM is characterized by its
significantly higher uptake by fibroblasts and acute
reactant cells, like polymorphonuclear leukocytes,
monocytes, and lymphocytes.26,27 The drug sub-
sequently is delivered and released in high con-
centrations to phagocytosed bacteria at the site of
infection.28 Because of a long half-life, shorter regi-
mens are required.29 This property theoretically leads
to increased patient compliance. Side effects are rare
and usually minor, and they include gastrointestinal
problems, such as diarrhea, nausea, abdominal pain,
and vomiting. AZM has significantly less bacterial re-
sistance to subgingival microflora of adult periodonti-
tis compared to other commonly prescribed oral
antibiotics.30
AZM improved clinical parameters when used as an
adjunct to SRP.31,32 Recently, Mascarenhas et al.33
conducted a randomized clinical trial evaluating the
use of systemic AZM in conjunction with SRP in heavy
smokers (more than one pack/day), a patient popu-
lation similar to the one used in the present study.
They found improvements in clinical parameters (PD
reduction and CAL gain), cross-linked telopeptide of
type I collagen (ICTP) levels, and benzoyl-DL-arginine
naphthylamine (BANA) levels.
Hence, the aim of this double-masked, random-
ized, placebo-controlled clinical trial was to determine
whether the use of adjunctive systemic AZM improved
the outcomes of periodontal pocket reduction surgery
for the treatment of moderate to severe chronic peri-
odontitis in heavy smokers.
MATERIALS AND METHODS
This study was a single-center, double-masked, ran-
domized, placebo-controlled clinical trial that
evaluated the effect of adjunctive systemic AZM fol-
lowing periodontal pocket reduction surgery in heavy
smokers with moderate to advanced chronic peri-
odontitis. The use of human subjects was approved
by the Health Sciences Institutional Review Board of
the University of Michigan in August 2004. Thirty pa-
tients with generalized moderate to advanced chronic
periodontitis were recruited from the patient popula-
tion at the University of Michigan School of Dentistry
between January 2005 and December 2005. Patients
completed a health history questionnaire to ensure
that they were medically qualified for participation
in the study. After patients were screened and deter-
mined to be eligible for participation, an informed
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consent was obtained. All patients were at least 30
years old, smoked at least one pack of cigarettes/
day, had ‡10 teeth in their functional dentition, ex-
cluding third molars, and had at least two posterior
teeth with PD ‡5 mm and bleeding on probing
(BOP) that were deemed in need of periodontal sur-
gery. Patients who had teeth that were candidates
for regenerative therapy were not included in the
study. Generally, the quadrant with the most active
disease, as evidenced by the most number of peri-
odontal pockets with active disease, was selected for
treatment. All patients completed initial periodontal
therapy (SRP) within 90 days prior to inclusion in
the study and demonstrated adequate oral hygiene
levels (plaque score £20%). The other quadrants did
not receive further non-surgical therapy.
Preoperatively, a 0.12% chlorhexidine rinse and
ibuprofen, 600 mg, were given to all patients. After
local anesthesia administration, periodontal surgery
was performed (apically positioned flap with osseous
recontouring) by second- and third-year residents at
the Graduate Periodontics Clinic, University of Michi-
gan School of Dentistry. The final osseous contour
and suturing were done by a single surgeon (SD) to
ensure standardization of surgical treatment. Post-
operative instructions were given in written and oral
formats.
The placebo and AZM tablets were provided by the
Investigational Drug Service at the University of Mich-
igan hospital pharmacy. After surgery, patients were
assigned randomly to the test (active AZM, 500 mg for
3 days; 1 tablet per day) or control group (placebo
containing inactive ingredients for 3 days; 1 tablet
per day) via a computer-generated list that was pre-
pared by an independent study coordinator. Tablets
were taken 1 hour before or 2 hours after meals, pref-
erably on an empty stomach. Patients returning to the
clinic for subsequent examinations were instructed to
return any residual tablets for measurement of drug
compliance. Drug compliance was determined by
verbally asking the patients if they consumed all tab-
lets as directed, requesting that they return to the
2-week appointment with the vial that contained the
medication/placebo, and counting how many tablets
remained.
Postoperative analgesia was provided through
non-steroidal anti-inflammatory drugs (ibuprofen,
600 mg every 6 hours for 2 days, and thereafter as
needed). Patients were asked to rinse with 0.12% chlor-
hexidine twice a day for 2 weeks following surgery
and to refrain from oral hygiene procedures in the
quadrant that received surgery. Following surgery,
patients returned for examinations at 2 weeks and
at 1, 3, and 6 months, at which time various clinical
parameters were measured or recorded by single,
masked examiner. Calibration trials were performed
prior to the study to ensure adequate intra- and inter-
examiner reproducibility (kappa statistic ‡90%). All
measurements were performed using a standard Uni-
versity of North Carolina probe with millimeter mark-
ings (0.28 mm in diameter).‡ Maintenance therapy
was performed by the examiner at 3 and 6 months
after surgical intervention. From an ethical stand-
point, smoking cessation was advised for all patients
throughout the study.
Clinical Parameters
The clinical parameters that were evaluated in this
study and the time points at which they were mea-
sured are shown in Table 1. PD, CAL, and BOP were
assessed for all teeth in the surgical quadrant at six
locations around the tooth (mesio-buccal, buccal,
disto-buccal, mesio-lingual, lingual, and disto-lin-
gual) at baseline and at 3 and 6 months following sur-
gical intervention. Gingival index (GI) and plaque
index (PI) were assessed at baseline and at 2 weeks
and 1, 3, and 6 months following surgery. PD, CAL,
and BOP were assessed at baseline and 6 months
for all other teeth in the mouth that did not receive
periodontal surgery. These ‘‘non-surgery’’ teeth only
received the initial non-surgical therapy. A wound
healing index (WHI) score was assigned as an overall
score of 1 (optimal) to 3 (least optimal) for the entire
surgical quadrant.34 Descriptions of the three possible
scores are as follows: 1 = uneventful wound healing
with no gingival edema, erythema, suppuration, pa-
tient discomfort, or flap dehiscence; 2 = uneventful
wound healing with slight gingival edema, erythema,
or patient discomfort, but slight flap dehiscence and
no suppuration; and 3 = poor wound healing with
significant gingival edema, erythema, patient discom-
fort, significant flap dehiscence, or any suppuration.
Microbial Assessments: BANA Test
The BANA test§ is a chair-side test that is highly sen-
sitive and specific for determining the presence of
‘‘red-complex’’ periodontal pathogens (Porphyromo-
nas gingivalis, Treponema denticola, and Tannerella
forsythia [previously T. forsythensis]).35 These path-
ogens have been implicated in periodontal disease in-
itiation and progression,36,37 and they are capable of
hydrolyzing a synthetic trypsin substrate (BANA).
Plaque was collected for BANA analysis from the me-
sio-buccal aspect of two posterior teeth in the surgical
quadrant with PD ‡5 mm at baseline and at 2 weeks
and 1, 3, and 6 months following surgery. A separate
toothpicki was used for plaque collection for each site.
After incubation for 5 minutes at 35C with Evan’s
black dye solution, naphthylamine released as a result
of the presence of any one of the BANA-hydrolyzing
‡ Model UNC-15, Hu-Friedy, Chicago, IL.
§ Perioscan, Oral-B, Redwood City, CA.
i Stim-U-Dent, Johnson and Johnson, Windsor, NJ.
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bacterial species diffuses to form a permanent blue-
black color. Assessments were made regarding the
relative intensity of the bluecolor (strong positive, pos-
itive, or negative).
Gingival Crevicular Fluid Sampling
ICTP is a specific marker of bone resorption. The frag-
ment is released by digestion with trypsin or bacterial
collagenase,38 and its presence is correlated with
bone resorption and the presence of periopathogenic
bacteria.39,40 Gingival crevicular fluid (GCF) was col-
lected, prior to any clinical measurements, from the
mesio-buccal aspect of two teeth in the surgical quad-
rant at baseline and at 2 weeks and 1, 3, and 6 months
following surgical intervention. Each tooth was dried
with gauze, and the supragingival plaque was re-
moved. GCF was collected for 10 seconds using
methylcellulose strips¶ placed gently until slight resis-
tance was felt. Following collection, the samples were
kept on dry ice for transport to the laboratory and stor-
age at -80C until analyzed. Samples were analyzed
for ICTP as described by Giannobile et al.39
Statistical Analysis
The results of this study were analyzed by presenting
descriptive statistics and making comparisons be-
tween treatment groups with respect to demographics
and efficacy parameters. Data were analyzed on a
subject basis. Mean values and standard errors for
PD, CAL, BOP, GI, PI, WHI, ICTP, and BANA were cal-
culated for each subject at each time point. Data were
divided, based on baseline PD, into three categories:
shallow sites (PD from 1 to 3 mm), moderate sites (PD
from 4 to 6 mm), and deep sites (PD >6 mm). Means
and standard errors for PD and CAL of the sites within
each baseline category were obtained for each time
point. Differences between groups were sought using
the repeated measures of variance (analysis of var-
iance) test using a statistical software program.#
Differences with a P value <0.05 at a confidence level
of 95% were considered significant.
RESULTS
Table 2 depicts the baseline demographic and clinical
characteristics of each group. Thirty patients were en-
rolled in this study (17 males and 13 females). Of the
15 patients in the test group, six were male; the aver-
age age of the patients in this group was 49.40 – 7.81
years. Of the 15 patients in the control group, 11 were
male; the average age of patients in this group was
52.00 – 8.36 years. There were no statistically sig-
nificant baseline differences between groups for any
demographic or clinical parameter for surgery and
non-surgery teeth. All subjects completed the study,
and none decreased their smoking habit to less than
one pack of cigarettes/day. The overall drug compli-
ance rate was 100%, and all patients consumed the
medications as they were directed. No adverse drug
reactions were reported at any time.
Overall PD, CAL, and BOP
Overall mean PD and CAL changes are given in Table
1. Negative values denote improvement for the ob-
served parameter. No statistically significant treatment-
related differences were found at any time point for
Table 1.
Effect of Systemic Administration of AZM in Combination With Surgery or Surgery
Alone on Overall PD, CAL, and Percentage of Sites With BOP (mean – SEM) for
Surgery and Non-Surgery Teeth
Tooth Type Parameter Baseline 3 Months (change)* 6 Months (change)*
Surgery teeth PD (mm) T: 3.10 – 0.34 T: -1.03 – 0.01† T: -0.83 – 0.10†
C: 3.21 – 0.65 C: -1.02 – 0.24† C: -0.98 – 0.03†
CAL (mm) T: 3.26 – 0.72 T: -0.22 – 0.02 T: -0.26 – 0.00
C: 3.59 – 1.13 C: -0.30 – 0.07 C: -0.03 – 0.07
BOP (% of sites) T: 66 – 21 T: -32 – 6† T: -22 – 4†
C: 61 – 20 C: -26 – 9† C: -27 – 1†
Non-surgery teeth PD (mm) T: 2.80 – 0.32 T: -0.27 – 0.04†
C: 3.01 – 0.62 C: -0.39 – 0.22†
CAL (mm) T: 2.96 – 0.84 T: -0.27 – 0.11†
C: 3.57 – 1.26 C: -0.16 – 0.09
BOP (% of sites) T: 49 – 17 T: -13 – 3†
C: 48 – 21 C: -15 – 1†
T = test group; C = control group.
* A negative value indicates improvement.
† Statistical significance between baseline and observed time point.
¶ ProFlow, Amityville, NY.
# SPSS, version 13.0, SPSS, Chicago, IL.
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PD, CAL, or BOP. At 6 months following surgical ther-
apy, test and control groups of surgically treated sites
demonstrated statistically significant reductions in PD
(-0.83 and -0.98 mm for test and control groups, re-
spectively). There was a trend (differences between
the observed time point and baseline not statistically
significant, i.e., P ‡0.05) for a slight rebound in PD in
both groups between 3 and 6 months. Overall mean
CAL remained unchanged for both groups; however,
the data indicated a trend for CAL loss in the control
group only. Regarding non-surgically treated sites,
there were statistically significant reductions in PD
for both groups at 6 months (-0.27 and -0.39 mm
for test and control groups, respectively). At 6 months,
only the test group had statistically significant gains in
CAL (-0.27 mm) compared to baseline. Nonetheless,
there were no significant differences between the
groups at any time point for PD or CAL. The percent-
age of sites that exhibited BOP at various time points is
shown in Table 1. For the surgery teeth, both groups
had statistically significant reductions at 3 months
compared to baseline. These reductions were sus-
tained through 6 months (-22% and -27% for test
and control groups, respectively). Teeth that were
treated non-surgically responded in a similar fashion
(-13% and -15% for test and control groups, respec-
tively).
Shallow Sites: Baseline PD From 1 to 3 mm
Shallow sites of surgically treated teeth showed statis-
tically significant PD reductions at 6 months (-0.32
and -0.15 in test and control groups, respectively),
with trends for rebound in PD between 3 and 6 months.
Although the placebo group had significant CAL loss
by 6 months compared to baseline (+0.27 mm), the
AZM group showed a trend for slight CAL gain. PD
and CAL for sites that were treated non-surgically
remained unchanged in both groups for the duration
of the study.
Moderate Sites: Baseline PD From 4 to 6 mm
Just as in the shallow sites, PD reduction of initially
moderate sites of the surgically treated teeth was ev-
ident at 6 months (-1.83 and -1.93 mm in test and
control groups, respectively). Significant gains of
CAL also were noted (-0.89 and -0.51 mm for test
and control groups, respectively); between 3 and 6
months, there was a slight trend for CAL loss in the
placebo group, whereas it appeared that initial CAL
gain was sustained in the AZM group. Non-surgically
treated sites responded in a similar fashion by having
significant reductions of PD at 6 months (-0.94 and
-1.01 mm for test and control groups, respectively)
and gains in CAL (-0.98 and -0.55 mm for test and
control groups, respectively).
Deep Sites: Baseline PD >6 mm
For the surgically treated sites, statistically significant
PD reduction was evident at 6 months following treat-
ment (-2.83 mm for the test group and -3.78 mm for
the control group). As in the other PD strata, both
groups showed trends for rebound in PD between
3 and 6 months. Regarding CAL, only the placebo
group had statistically significant gains in CAL at
6 months (-0.40 mm); the test group remained
Table 2.
Mean Baseline Clinical Characteristics of the Study Groups
Parameter Test (N = 15) Control (N = 15) P Value*
Age (years; mean – SEM [range]) 49.40 – 7.81 (35 to 65) 52.00 – 8.36 (36 to 67) NS
Male/female ratio 2:3 11:4 NS
PD (mm; mean – SEM) Overall: 2.95 – 0.36 Overall: 3.11 – 0.63 NS
Sx teeth: 3.10 – 0.34 Sx-teeth: 3.21 – 0.65 NS
Non-sx teeth: 2.80 – 0.32 Non-sx teeth: 3.01 – 0.62 NS
CAL (mm; mean – SEM) Overall: 3.12 – 0.78 Overall: 3.58 – 1.17 NS
Sx teeth: 3.26 – 0.72 Sx teeth: 3.59 – 1.13 NS
Non-sx teeth: 2.96 – 0.84 Non-sx teeth: 3.57 – 1.26 NS
BOP (% of sites; mean – SEM) Overall: 57.52 – 20.71 Overall: 54.50 – 21.63 NS
Sx teeth: 65.60 – 21.35 Sx teeth: 61.46 – 20.47 NS
Non-sx teeth: 48.87 – 16.65 Non-sx teeth: 47.54 – 21.12 NS
ICTP (pg/site; mean – SEM) 11.43 – 13.62 22.92 – 64.41 NS
BANA score (mean – SEM) 0.87 – 0.48 1.00 – 0.60 NS
NS = not statistically significant; sx = surgery.
* Based on the non-parametric Mann-Whitney test.
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unchanged. Non-surgically treated sites had statisti-
cally significant reductions in PD (-2.00 and -2.76
mm in test and control groups, respectively) and sta-
tistically significant gains in CAL (-1.33 mm in the test
group and -1.95 mm in the control group).
PI and GI
Table 3 depicts changes in PI and GI for both groups
during the study period. At the 2-week postoperative
appointment, there was a trend for an increased PI
score in the control group and a decreased PI score
in the test group, compared to baseline. The differ-
ence between study groups was marginally significant
(P = 0.089). Consequently, at this time point, only the
control group had a significantly worse GI score com-
pared to baseline. By 3 months, both groups had sta-
tistically significantly better GI scores compared to
baseline. This improvement was sustained through
6 months only in the control group.
WHI
Table 3 depicts the WHI score for both groups through-
out the study. Two weeks following surgery, both
groups had similar WHI scores. One month after sur-
gery, only the AZM group had a statistically signifi-
cantly better WHI score compared to baseline, and
it showed statistically significantly better wound heal-
ing than the placebo group. By 3 months, there was
complete wound healing in all patients, yielding statis-
tically significantly better wound healing for both
groups compared to baseline.
BANA
Table 4 shows the changes in BANA scores for both
groups during the study. There was a statistically sig-
nificant reduction in BANA scores for both groups
2 weeks after surgery (-0.88 – 0.30 and -0.77 – 0.07
for test and control groups, respectively). By 3 months,
BANA scores in the placebo group rebounded to
baseline levels, whereas the initial reduction was sus-
tained in the AZM group. By 6 months, BANA scores
in both groups rebounded to baseline levels. Never-
theless, no significant differences were found between
the groups at any time point.
ICTP
Table 4 shows the changes in ICTP levels for both
groups during the study. No statistically significant
differences, compared to baseline, were found for ei-
ther group at any time point. Additionally, there were
Table 3.
Effect of Systemic Administration of AZM in Combination With Surgery or Surgery
Alone on PI, GI, and WHI (mean – SEM)
Parameter Baseline 2 Weeks (change)* 1 Month (change)* 3 Months (change)* 6 Months (change)*
PI T: 0.89 – 0.38 T: -0.26 – 0.00 T: -0.25 – 0.02 T: -0.25 – 0.01 T: -0.15 – 0.05
C: 0.82 – 0.37 C: +0.08 – 0.01 C: -0.0.5 – 0.01 C: -0.15 – 0.12 C: -0.29 – 0.00
GI T: 1.36 – 0.37 T: +0.04 – 0.06 T: -0.33 – 0.03 T: -0.64 – 0.03† T: -0.22 – 0.04‡
C: 1.23 – 0.38 C: +0.39 – 0.03† C: -0.07 – 0.19 C: -0.46 – 0.17† C: -0.50 – 0.16†‡
WHI T: 1.73 – 0.46 T: -0.46 – 0.00†‡ T: -0.73 – 0.46† T: -0.73 – 0.46†
C: 1.93 – 0.26 C: -0.26 – 0.23‡ C: -0.93 – 0.26† C: -0.93 – 0.26†
T = test group; C = control group.
* A negative value indicates improvement.
† Statistical significance between baseline and observed time point.
‡ Statistical significance between groups.
Table 4.
Effect of Systemic Administration of AZM in Combination With Surgery or Surgery Alone
on BANA and ICTP Levels (mean – SEM)
Parameter Baseline 2 Weeks (change)* 1 Month (change)* 3 Months (change)* 6 Months (change)*
BANA T: 0.87 – 0.48 T: -0.80 – 0.30† T: -0.60 – 0.11† T: -0.54 – 0.49† T: -0.33 – 0.02
C: 1.00 – 0.60 C: -0.77 – 0.07† C: -0.74 – 0.35† C: -0.46 – 0.06 C: -0.23 – 0.14
ICTP (pg/site) T: 11.43 – 13.62 T: +1.23 – 1.84 T: -6.04 – 7.01 T: +0.94 – 1.50 T: -3.83 – 2.72
C: 22.93 – 64.41 C: -6.66 – 47.49 C: -11.49 – 44.87 C: -12.81 – 12.48 C: -7.36 – 34.77
T = test group; C = control group.
* A negative value indicates improvement.
† Statistical significance between baseline and observed time point.
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no statistically significant differences between groups
at any time point.
DISCUSSION
Providing successful periodontal treatment for heavy
smokers often is frustrating because they tend to have
a less favorable therapeutic response to non-surgical
or surgical therapy compared to non-smokers.41,42
This longitudinal, doubled-masked, randomized clin-
ical trial was designed to evaluate if the outcomes of
surgical therapy in heavy smokers could be enhanced
by the adjunctive administration of systemic AZM, be-
cause of its high tissue concentration and increased
patient compliance.
Regarding the surgically treated sites, both groups
demonstrated statistically significant overall mean PD
reduction; however, a slight, but non-significant, re-
bound in PD was noted in both groups between 3
and 6 months. This trend might be explained by the
fact that none of the patients decreased their smoking
habit to less than one pack of cigarettes per day
throughout the study. The prolonged local and sys-
temic effects of nicotine and other harmful by-pro-
ducts of cigarette smoke possibly overwhelmed the
initial short-term benefit of the surgery and/or the an-
tibiotic. Recurrent colonization of periodontal pockets
by periopathogenic bacteria and continued long-term
alterations of host defense systems would be inevita-
ble in such heavy smokers, thus promoting the dis-
ease process to continue. Additionally, Tonetti et al.19
demonstrated that heavy smokers tend to harbor
more plaque than non-smokers. Increased plaque
levels in such patients may explain, in part, the
smokers’ inability to sustain PD reduction. Because
the follow-up for the present study was only 6 months,
it would be interesting to evaluate how long the initial
PD reduction could be sustained in each of the treated
groups.
For a more accurate and detailed analysis of these
findings, data were stratified according to baseline PD.
Shallow (PD: 1 to 3 mm), moderate (PD: 4 to 6 mm),
and deep pockets (PD >6 mm) for both groups
showed statistically significant reductions in PD at 3
and 6 months, compared to baseline. These findings
are in agreement with previous studies that indicated
slight reductions in PD for shallow pockets and
more pronounced reductions in moderate and deep
pockets after osseous surgery.7,10 Again, the non-sig-
nificant rebound in PD for both groups between 3 and
6 months may be attributed to the prolonged harmful
effects of heavy smoking.
This study demonstrated no statistically significant
differences for PD between groups for any baseline PD
category at any time point. It seems that the periodon-
tal surgery was responsible for most of the PD reduc-
tion. The decrease in the percentage of sites with BOP
correlated with the decrease in PD for both groups at
3 and 6 months following surgical intervention. It is
well documented that shallow PD promotes less colo-
nization of periopathogenic bacteria which, in turn,
yields less collagen breakdown, less gingival inflam-
mation, and thus, less BOP.9,43,44 As expected, the
reduction in BOP correlated with statistically signifi-
cant reductions in plaque (PI) at 3 and 6 months.
Both groups did not demonstrate significant
changes in overall mean CAL of surgically treated
sites compared to baseline. Between 3 and 6 months,
there was a trend for CAL loss in the placebo group,
whereas it seemed that the CAL gain in the AZM group
was sustained. Additionally, at 6 months, only the
AZM group had statistically significant gains in overall
CAL of non-surgically treated sites. These findings
may be explained by the sustained effect of the anti-
biotic.
When data were stratified according to baseline PD,
shallow sites of the placebo group had a statistically
significant loss of CAL at 6 months compared to base-
line. This CAL loss was not evident in the AZM group.
Many studies7,10,45 demonstrated a slight loss of CAL
after PD reduction surgery in shallow sites (;0.80
mm). The adjunctive administration of AZM seemed
to play a pivotal role in preventing this expected CAL,
which is certainly of clinical benefit. For moderate
sites that were treated surgically, a statistically signif-
icant gain of CAL was found in both groups at 3 and 6
months. Between 3 and 6 months, the placebo group
showed a trend for CAL loss, whereas the AZM group
did not. The value of the antibiotic in heavy smokers
can be appreciated in maintaining CAL gain observed
after surgery. For sites with initially deep PD, only the
placebo group had a statistically significant gain of
CAL at 6 months compared to baseline. This finding
may be attributed to not having an adequate amount
of sites that were initially ‡7 mm in either group. Be-
cause of the small sample size, a proper statistical
analysis was not possible. However, overall, our data
are in agreement with previous studies that demon-
strated a gain in CAL for initially moderate and deep
pockets following pocket reduction surgery.6,10,46
When data were stratified according to baseline PD
and analyzed for the non-surgically treated sites, sim-
ilar results were found. At 6 months, despite not being
treated surgically, these sites in both groups demon-
strated statistically significant reductions in overall PD
and BOP and statistically significant CAL gain in mod-
erate and deep pockets. BOP is an indicator of colla-
gen breakdown and gingival inflammation, and it is
significant that it was reduced in sites that did not re-
ceive surgery. Our findings were similar to the results
observed by Levy et al.;9 they found a decline in the
proportion of red-complex bacteria in non-surgically
treated sites 1 year after apically positioned flap
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surgery with osseous resection had been performed in
another quadrant of the mouth. These findings may
explain the PD reduction that was evident in non-sur-
gically treated sites in our study. In an already peri-
odontally compromised patient population, such as
heavy smokers, performing PD reduction surgery in
even one quadrant may have long-term beneficial
effects for other areas of the mouth by decreasing
the overall bacterial load.
The hypothesis that AZM may lead to faster wound
healing in heavy smokers who receive periodontal
surgery was confirmed in our study. After having com-
parable WHI scores at 2 weeks following surgery, only
the AZM group showed a statistically significantly
higher WHI score at 1 month compared to baseline
(yielding a statistically significant difference between
groups). It can be hypothesized that the antibiotic’s
effect of targeting tissue-invasive bacteria contributed
to these findings. Reducing the proportions of these
bacteria via antibiotics decreases the effects of colle-
genases and other inflammatory mediators that lead
to gingival inflammation.
Data from the BANA analysis support the hypoth-
esis that AZM could help to diminish the proportion of
red-complex bacteria, at least in the short-term. Re-
duction of red-complex bacteria following PD reduc-
tion surgery, which was found in our study for both
treatment groups, is in agreement with a previous
study that demonstrated that shallower periodontal
pockets harbor lower levels of periodontal pathogens
than deeper pockets.47 At 3 months post-surgery, de-
spite continued heavy smoking, only the AZM group
sustained statistically significant reductions in BANA
scores, whereas those in the control group increased
to baseline levels. This implied that the adjunctive ad-
ministration of AZM with periodontal surgery may be
more beneficial than surgery alone in eliminating tis-
sue-invasive pathogens. Mascarenhas et al.,33 using
the same antibiotic after SRP, also showed sustained
reductions in BANA scores in the AZM group but not in
the control group. At 6 months, BANA scores in both
groups returned to baseline levels. This inability to
sustain reductions in red-complex bacteria is in agree-
ment with previous investigations48,49 that showed
that a single episode of antibiotic therapy resulted in
initial decreases of periopathogenic bacteria; how-
ever, recolonization, almost to baseline levels, oc-
curred by 6 months. Future clinical trials are needed
to evaluate the possible benefit of repeated admin-
istration of systemic antibiotics, especially in heavy
smokers.
Our study found no statistically significant changes
regarding mean ICTP levels over the study period,
with no significant differences between treatment
groups at any time point. This is contradictory to pre-
viously published papers.50,51 However, those studies
evaluated the effect of tetracycline derivatives, which
are more effective at reducing ICTP levels than other
antibiotics. Another explanation for these findings
may be that, in our study, all patients received non-
surgical therapy ;4 to 6 weeks before surgical treat-
ment, which may have been responsible for much of
the reduction of GCF ICTP. Mascarenhas et al.,33 in a
similar population of heavy smokers, showed that
non-surgical therapy produced short-term reductions
of GCF ICTP that rebounded to baseline levels by
3 months. Similarly, Al-Shammari et al.50 demon-
strated in a longitudinal trial that the initial reductions
of GCF ICTP became less obvious at 3 months follow-
ing SRP. Because surgical therapy was performed
within 3 months following initial therapy in the pres-
ent study, it is reasonable to assume that GCF ICTP
levels were still low enough that an accurate analy-
sis of the effect of treatment on GCF ICTP was not
possible.
CONCLUSIONS
Data from our pilot study suggested that surgical
treatment of moderate and deep periodontal pockets
in heavy smokers improved clinical outcomes, e.g.,
CAL gain, PD reduction, and reduction of BOP. The
adjunctive administration of systemic AZM to surgical
treatment did not improve overall PD reduction, CAL
gain, or reduction of the bone resorption marker ICTP
compared to sites that received surgical treatment
only. For the non-surgery teeth, the systemic admin-
istration of AZM yielded significant gains in overall
CAL compared to baseline, whereas placebo did
not. The addition of AZM during periodontal surgery
in heavy smokers promoted rapid wound healing, re-
duced short-term gingival inflammation, and resulted
in less plaque formation within 3 months. AZM’s ben-
eficial properties, such as the rare incidence of side
effects, decreased bacterial resistance compared to
common antibiotics, and increased patient compli-
ance because of shorter dosage regimens, suggests
that its benefits might outweigh the risks when using
it in conjunction with non-surgical or surgical ther-
apy in heavy smokers. Larger, controlled clinical
trials are needed to confirm the findings of this study.
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